We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App





Sebia Presents Innovative Solutions for Screening and Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)

Sebia (Lisses, France) is showcasing its innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases at WorldLab–EuroMedLab Roma 2023.

At EuroMedLab Rome 2023, Sebia is highlighting the new Alegria 2 instrument, a fully automated, sample-to-result solution. The instrument utilizes ORGENTEC’s unique and comprehensive Alegria Monotest portfolio, boasting over 100 parameters. A key distinguishing feature of the Alegria system is its flexibility to run any test from the wide ORGENTEC portfolio at any given time. Physicians can request tailor-made biomarker profiles to be analyzed for individual patients, ensuring the best possible patient care.

Sebia is presenting its CAPILLARYS 3 range of capillary electrophoresis (CE) instruments, designed for complete automation, rapid protein separation, and high resolution. The Sebia CE instruments are equipped with several parallel capillaries, enabling multiple analyses to be carried out simultaneously, offering scalable throughput. The Sebia CAPILLARYS instruments are currently the most widely used CE systems in clinical labs globally. Alongside its CE capabilities, Sebia is highlighting its gel technique-based solutions. These are implemented on the HYDRASYS instruments to separate hemoglobins and detect major hemoglobin variants via electrophoresis on alkaline agarose gels.

Leveraging its extensive experience in CE technology, Sebia has also adapted it for HbA1c testing, which is being showcased at WorldLab–EuroMedLab Roma 2023. This cutting-edge technology offers labs and clinicians accurate and significant results, enhancing patient management. The clear and precise separation of different hemoglobin fractions enables accurate HbA1c measurement due to the high-resolution separation capabilities of the capillary instruments. Given Sebia’s wide offering of capillary instruments, laboratories have the freedom to choose the platform that best suits their needs, ranging from a benchtop standalone instrument to the TLA configuration.

Related Links:
Sebia

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Procalcitonin Rapid Test
StrongStep Procalcitonin Test
New
Multi-Channel Pipettor
BioPette Plus

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.